Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations

References

• EUCERD recommendation for a CAVOMP information flow [webpage on the Internet]. Luxembourg: European Union Committee of Experts on Rare Diseases (EUCERD); 2012. Available from: http://www.eucerd.eu/?post_type=document&p=1446. Accessed November 2, 2013.
   Google Scholar
• European Union High Level Pharmaceutical Forum 2005–2008. Final conclusions and recommendations. Brussels: European Commission; 2008. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/pharmaforum_final_conclusions_en.pdf. Accessed November 2, 2013.
   Google Scholar
• Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011;71(4):488–496.
   PubMed Web of Science ®Google Scholar
• Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria. Health Policy. 2012;108(1):10–18.
   PubMed Web of Science ®Google Scholar
• Drummond M, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases – a case study in oncology. Can J Clin Pharmacol. 2009;16(2):e273–e281; discussion e282–e284.
   Google Scholar
• Trask LS. Chapter 1. Pharmacoeconomics: principles, methods, and applications. In: Wells BG, editor. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2011.
   Google Scholar
• Miyamoto BE, Kakkis ED. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis. 2011;6:49.
   Web of Science ®Google Scholar
• Le Jeunne C. [Assessment of actual benefits of new drugs by the Transparency Committee]. J Fr Ophtalmol. 2008;31(1):90–93. French.
   Web of Science ®Google Scholar
• Drummond M, Brixner D, Gold M, Kind P, McGuire A, Nord E; Consensus Development Group. Toward a consensus on the QALY. Value Health. 2009;12 Suppl 1:S31–S35.
   Google Scholar
• Schlander M. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process. J Med Ethics. 2008;34(7):534–539.
   PubMed Web of Science ®Google Scholar
• Weinstein MC. The cost-effectiveness of orphan drugs. Am J Public Health. 1991;81(4):414–415.
   Web of Science ®Google Scholar
• Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–744.
   PubMed Web of Science ®Google Scholar
• Drummond MF. Challenges in the economic evaluation of orphan drugs. Eurohealth. 2008;14(2):16–17.
   Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysis. Value Health. 2007;10(5):336–347.
   PubMed Web of Science ®Google Scholar
• Niezen MG, de Bont A, Busschbach JJ, Cohen JP, Stolk EA. Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care. 2009;25(1):49–55.
   Web of Science ®Google Scholar
• Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy. 2013;110(1):49–59.
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Chirila C, Masaquel C, et al. Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care. 2013;29(1):92–100.
   Web of Science ®Google Scholar
• Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13(2):295–301.
   PubMedGoogle Scholar
• De Varax A, Letellier M, Börtlein G; for Alcimed. Study on Orphan Drugs, 2004. Paris; Alcimed; 2004. Available from: http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf. Accessed November 2, 2013.
   Google Scholar
• Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011;6:62.
   PubMed Web of Science ®Google Scholar
• Rubinstein YR, Groft SC, Bartek R, et al. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemp Clin Trials. 2010;31(5):394–404.
   PubMed Web of Science ®Google Scholar
• Rosenberg-Yunger ZR, Daar AS, Thorsteinsdóttir H, Martin DK. Priority setting for orphan drugs: an international comparison. Health Policy. 2011;100(1):25–34.
   Web of Science ®Google Scholar
• Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc. 2006;4:14.
   PubMedGoogle Scholar
• Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health. 2008;11(4):771–783.
   PubMed Web of Science ®Google Scholar
• Koopmanschap MA, Stolk EA, Koolman X. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals. Int J Technol Assess Health Care. 2010;26(2):198–204.
   Web of Science ®Google Scholar
• Final report of the Working group on Mechanism of Coordinated Access to orphan medicinal products. Process on Corporate Responsibility in the field of Pharmaceuticals. Brussels: European Commission; 2013. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/orphans_report_en.pdf. Accessed November 2, 2013.
   Google Scholar